Versants, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and biopharmaceutical research.
Previously, VRS-859 was studied in preclinical animal models of T2DM to assess the drug’s pharmacokinetics (PK) in multiple animal species and to determine the relationship between PK and pharmacodynamics (PD).
Versartis, Inc. is an endocrine-focused biopharmaceutical company. It develops long-acting therapeutic proteins for the treatment of endocrine disorders. The company develops new therapeutic proteins utilizing the novel half-life extension technology XTEN. [Source: MarketWatch]
Company website: http://www.versartis.com